Swiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in the US, hoping to expand the number of women eligible for this type of
Amgen has chalked up a victory in a patent infringement lawsuit with Regeneron over blockbuster ophthalmic drug Eylea and decided to launch its biosimilar in the US – even though the legal